Aquestive Therapeutics (AQST) Soars 14.8%: Is Further Upside Left in the Stock?

Company Overview - Aquestive Therapeutics (AQST) shares increased by 14.8% to close at $5.67, with notable trading volume compared to typical sessions, and a total gain of 26.3% over the past four weeks [1][2] Regulatory Developments - The stock price surge is attributed to positive investor expectations regarding the FDA approval filing for its key product candidate, Anaphylm, aimed at treating severe allergic reactions. The FDA waived the advisory committee meeting, indicating a lower perceived risk associated with the treatment, with a final decision expected by January 31, 2026 [2] Financial Performance Expectations - The company is projected to report a quarterly loss of $0.13 per share, unchanged from the previous year, with expected revenues of $13.36 million, reflecting a 1.3% decline from the year-ago quarter [3] - The consensus EPS estimate for the quarter has been revised 24.4% higher over the last 30 days, suggesting a potential for price appreciation [4] Industry Comparison - Aquestive Therapeutics operates within the Zacks Medical - Drugs industry. In contrast, USANA Health Sciences (USNA) closed 3.6% lower at $29.74, with a 0.7% return over the past month. USANA's consensus EPS estimate remains unchanged at $0.47, representing a 16.1% decline from the previous year [4][5]